Jasper Therapeutics (JSPR) Other financing activities (2021 - 2025)

Jasper Therapeutics has reported Other financing activities for 5 years, with the latest figure at $20000.0 in Q4 2025.

• On a quarterly basis, Other financing activities fell 67.21% year-over-year to $20000.0 in Q4 2025; TTM through Dec 2025 was $90000.0, a 75.0% decrease from a year earlier, with the FY2025 full-year figure at $243000.0, down 32.5% from the prior year.
• Other financing activities was $20000.0 for Q4 2025 at Jasper Therapeutics, down from $61000.0 in the prior quarter.
• The five-year high for Other financing activities was $320000.0 in Q2 2023, with the low at $1000.0 in Q3 2022.
• Average Other financing activities over 5 years is $64437.5, with a median of $32500.0 recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Other financing activities slumped 99.24% in 2022, then jumped 3500.0% in 2023.
• Over 5 years, Other financing activities stood at $33000.0 in 2021, then sank by 96.97% to $1000.0 in 2022, then surged by 3500.0% to $36000.0 in 2023, then surged by 69.44% to $61000.0 in 2024, then sank by 67.21% to $20000.0 in 2025.
• The last three Other financing activities figures came in at $20000.0 (Q4 2025), $61000.0 (Q4 2024), and $9000.0 (Q3 2024), per Business Quant data.